# S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy

> **NCT02191566** · PHASE2 · TERMINATED · sponsor: **Kangbuk Samsung Hospital** · enrollment: 8 (actual)

## Conditions studied

- Stomach Cancer

## Interventions

- **DRUG:** S-1 (452500ACH)
- **DRUG:** OXALIPLATIN (205803BIJ)

## Key facts

- **NCT ID:** NCT02191566
- **Lead sponsor:** Kangbuk Samsung Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2019-10
- **Final completion:** 2019-10
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The patient's study enrollment was too low.
- **Last updated:** 2022-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02191566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02191566, "S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02191566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*